Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. reports developments from a clinical-stage biotechnology business focused on vaccines and immunotherapies for infectious diseases and cancer. Recurring updates cover its MVA-based vaccine platform, the GEO-MVA candidate for mpox, smallpox and other poxviruses, GEO-CM04S1 as a multi-antigen COVID-19 vaccine, and Gedeptin as an oncolytic gene-directed therapy for solid tumors.
Company news also includes clinical-trial data reviews, government-supported program updates, patent activity tied to MVA-VLP technology and MUC1 tumor-associated antigen immunotherapy, financial results, and corporate presentations at healthcare and growth-company conferences.
GeoVax Labs (Nasdaq: GOVX) announced the issuance of U.S. Patent No. 11,052,148 for a vaccine targeting the Hepatitis B virus, addressing an unmet therapeutic need for over 250 million people globally. This patent supports a modified vaccinia Ankara (MVA) vector designed to generate an immune response, applicable for both prevention and treatment of chronic HBV infections. The patent arises from a collaboration with Georgia State University. The company focuses on developing human immunotherapies and vaccines for infectious diseases and cancer.
GeoVax Labs, a biotechnology firm focused on human immunotherapies and vaccines, announced participation in the Alliance Global Partners’ Virtual Healthcare Symposium on June 17, 2021. The management team will conduct 1-on-1 investor meetings during the event. GeoVax's development programs target vaccines for COVID-19, Zika, Ebola, HIV, and various cancers, utilizing an innovative MVA-VLP platform that stimulates robust immune responses akin to natural infections. For meeting requests, contact AGP Events at agpevents@allianceg.com.
GeoVax Labs (Nasdaq: GOVX) will present at the 2021 BIO Digital event on June 10, focusing on its COVID-19 vaccine and cancer immunotherapy programs. CEO David Dodd will provide insights into the company's research and development efforts. A panel discussion titled, “Vaccine Business – Five Minutes of Fame or Five-Time Oscar Winner?” will take place on June 15 at 11:05am ET, featuring Dodd. GeoVax’s vaccine platform is centered on combating infectious diseases and cancers, utilizing a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) technology.
GeoVax Labs, Inc. (GOVX) reported significant updates in their Q1 2021 financial results, including a net loss of $1.56 million, a 163% increase from Q1 2020. Cash reserves improved to $20.8 million, bolstered by a $10.3 million stock offering and $3.2 million from warrant exercises. The company is advancing its COVID-19 vaccine, supported by a $3.2 million NIH grant, focusing on a universal vaccine to counter multiple variants. GeoVax's patent portfolio expanded to over 70 applications, enhancing its position in COVID-19 and cancer immunotherapy.
GeoVax Labs, Inc (NasdaqCM: GOVX) announced that Chairman & CEO David Dodd will participate in the Benzinga Global Small Cap Conference on May 13-14, 2021. Dodd will deliver a corporate presentation at 9:50am ET and join a panel discussion titled “Investing Post COVID – Back to the Fundamentals” at 11:50am ET on May 13. The panel will focus on healthcare investing in a post-COVID environment. Investors can also request one-on-one meetings with Dodd after the conference.
GeoVax Labs, Inc. (NASDAQ: GOVX) will report its first quarter 2021 financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing financial results and company updates. The call will include a Q&A session. GeoVax is a clinical-stage biotechnology firm specializing in vaccines for infectious diseases and cancer, using a patented MVA-VLP platform. Their current developments include vaccines for COVID-19, HIV, Zika Virus, and various cancers.
GeoVax Labs (NasdaqCM: GOVX) announced a Notice of Allowance for a patent on methods to generate an immune response to Hepatitis B Virus (HBV), a critical unmet medical need affecting over 250 million people globally. The patent is co-owned with Georgia State University, emphasizing collaboration in combating chronic HBV infections. While the company's main focus remains on COVID-19 vaccines and cancer therapies, the development of an HBV treatment is part of its long-term strategy. This patent adds to GeoVax's growing portfolio of over 70 patents.
GeoVax Labs, Inc. (GOVX, GOVXW) reported its 2020 financial results, showing a net loss of $3.0 million, up from $2.4 million in 2019. Grant revenues increased from $1.2 million to $1.8 million, primarily due to U.S. Department of Defense support for the Lassa Fever vaccine. As of December 31, 2020, cash balances rose significantly to $9.9 million, compared to $283,341 in 2019, supported by a $11.2 million public offering. The company is advancing its COVID-19 vaccine and immuno-oncology programs, with several data announcements expected in the first half of 2021.
GeoVax Labs (NasdaqCM: GOVX) announces participation in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. CEO David Dodd will present an overview of the company’s immunotherapy and vaccine R&D, focusing on its COVID-19 vaccine targeting various SARS-CoV-2 variants. Chief Scientific Officer Mark Newman, PhD, will join a panel on advancements in cancer immunotherapies. Investors can view the presentations by registering for the conference and can request one-on-one meetings with Dodd.
GeoVax Labs, Inc. (GOVX) has scheduled its 2020 financial results release for March 23, 2021, after market close. A conference call will follow on March 24, 2021, at 8:00 a.m. ET, to discuss these results and corporate updates. The company specializes in human immunotherapies and vaccines targeting infectious diseases and cancer, utilizing its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Upcoming developments include preventive vaccines for COVID-19, HIV, and other diseases, with potential human clinical trials managed with the National Institutes of Health.